| Justine Sever Chilelli, DO | |
|
2128 Chamber Center Dr., Lakeside Park, KY 41017 | |
| (859) 331-6525 | |
| (859) 331-6526 |
| Full Name | Justine Sever Chilelli |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Child & Adolescent Psychiatry |
| Location | 2128 Chamber Center Dr., Lakeside Park, Kentucky |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144549585 | NPI | - | NPPES |
| 7100464370 | Medicaid | KY |
| Entity Name | Tms Therapy Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538705280 PECOS PAC ID: 8729409040 Enrollment ID: O20200521003000 |
News Archive
Vice President Biden and Dr. Jill Biden will host a Cancer Moonshot Summit in Washington, D.C. at the White House. Cheryl Willman, MD, Director and CEO of The University of New Mexico Comprehensive Cancer Center, will attend.
Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid.
A statin drug commonly used to lower cholesterol is not effective in reducing the number and severity of flare ups from chronic obstructive pulmonary disease (COPD), according to the results of a large multicenter clinical trial designed and directed by Gerard J. Criner, MD, Director of Pulmonary and Critical Care Medicine at Temple University Hospital in Philadelphia, PA.
HRT in the early postmenopausal period is safe, and healthy women going through the first few years of the menopause who need HRT to relieve symptoms should have no fears about its use. This is the conclusion and clinical advice of the First Global Summit on Menopause-Related Issues, which was held in Zurich on March 29th and 30th, 2008.
The common belief that tumors arise via activation of a few genes that "drive" cancer development is unsupported by a widespread investigation into those genes and others in three large patient genetic databases, according to a study led by Yale Cancer Center researchers.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Justine Sever Chilelli, DO 2128 Chamber Center Dr., Lakeside Park, KY 41017 Ph: (859) 331-6525 | Justine Sever Chilelli, DO 2128 Chamber Center Dr., Lakeside Park, KY 41017 Ph: (859) 331-6525 |
News Archive
Vice President Biden and Dr. Jill Biden will host a Cancer Moonshot Summit in Washington, D.C. at the White House. Cheryl Willman, MD, Director and CEO of The University of New Mexico Comprehensive Cancer Center, will attend.
Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid.
A statin drug commonly used to lower cholesterol is not effective in reducing the number and severity of flare ups from chronic obstructive pulmonary disease (COPD), according to the results of a large multicenter clinical trial designed and directed by Gerard J. Criner, MD, Director of Pulmonary and Critical Care Medicine at Temple University Hospital in Philadelphia, PA.
HRT in the early postmenopausal period is safe, and healthy women going through the first few years of the menopause who need HRT to relieve symptoms should have no fears about its use. This is the conclusion and clinical advice of the First Global Summit on Menopause-Related Issues, which was held in Zurich on March 29th and 30th, 2008.
The common belief that tumors arise via activation of a few genes that "drive" cancer development is unsupported by a widespread investigation into those genes and others in three large patient genetic databases, according to a study led by Yale Cancer Center researchers.
› Verified 9 days ago